

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Jennifer Baker, MD (UCLA)	Speaker	None	• N/A
Aditya Bardia, MD (UCLA)	Speaker	 Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, Daiichi Sankyo, Astra Zeneca, Eli Lilly, Alyssum Pfizer, Novartis, Genentech, Merck, Menarini, Gilead, Sanofi, Daiichi Sankyo, Astra Zeneca, Eli Lilly 	 Consultant Research Funding
Thomas Buchholz, MD (Scripps)	Course Director, Speaker, Moderator	Nucleix, Empyrean	Stock Options
Nancy Davidson, MD (Fred Hutch)	Speaker	Zymeworks	Board of Directors, Stock Options
Frederick Dirbas, MD (Stanford)	Speaker	• None	• N/A
Monica Dua, MD (Stanford)	Speaker	• None	• N/A
Jared Forrester, MD (Hoag)	Speaker	GE Foundation	Grant Funding
Kelly Hunt, MD (MD Anderson)	Speaker	 Armada Health, AstraZeneca Cairn Surgical, Eli Lilly, Lumicell 	 Advisory Board Funding to Institution, Researcher
Tyler Johnson, MD (Stanford)	Speaker	• None	• N/A
Shane Mesko, MD (Scripps)	Speaker	None	• N/A
Farah Nasraty, MD (Scripps)	Speaker	None	• N/A
Jacob New, MD (Scripps)	Speaker	None	• N/A
Mark Onaitis, MD (UCSD)	Speaker	None	• N/A
Aditya Sarvaria, MD (Scripps)	Speaker	None	• N/A
Darren Sigal, MD (Scripps)	Speaker	 Ipsen Seagen/Pfizer Agenus, BMS 	 Speakers Bureau, Consultant Speakers Bureau Advisory Board
Stephen Swisher, MD (MD Anderson)	Speaker	None	• N/A

Oncology Review 2025



Conference Services & CME

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
CME Committee	CE approval, all final decision-making on activities	• None	• N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	• None	• N/A

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit <u>www.accme.org/standards</u>.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.

Oncology Review 2025

July 12, 2025 • Hyatt Regency Monterey • Monterey, California August 9, 2025 • Hyatt Regency Mission Bay • San Diego, California August 23, 2025 • Hyatt Regency Newport Beach • Newport Beach, California